At LSI 2021, Mr. Persson will share the story of Acarix and provide timely updates to an audience of medtech investors, strategics, and industry insiders.
Objective: Provide a much needed in-person investment/networking event focused on medtech innovation
When: February 17-19, 2021
Where: The Ritz-Carlton, Dana Point, CA
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, email@example.com) is Certified Advisor of Acarix.